RO5256390

RO5256390 is a synthetic oxazoline-class full agonist of trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor expressed in monoaminergic nuclei of the central nervous system and implicated in the modulation of dopaminergic, serotonergic, and glutamatergic neurotransmission. The compound was developed at the Neuroscience Research division of Hoffmann-La Roche in Basel, Switzerland, and first reported in the seminal Revel et al. (2013) publication in Molecular Psychiatry, which characterized the TAAR1 agonist class as a mechanistically novel approach to the pharmacotherapy of schizophrenia, depression, cognitive dysfunction, and metabolic disturbance [1]. RO5256390 activates human TAAR1 with an EC50 of approximately 16 nM and maximal efficacy (Emax) of 98 percent relative to the endogenous agonist beta-phenylethylamine, qualifying it as a full agonist at the human, rat, and cynomolgus monkey receptor; at the mouse receptor, efficacy is reduced to 68 to 79 percent, placing it in the high-efficacy partial agonist range for that species [1, 2]. Selectivity is high; the compound was reported inactive against a panel of more than 100 molecular targets including dopamine D1 through D5, serotonin 5-HT1 through 5-HT7, adrenergic alpha and beta, muscarinic, histamine, opioid, and ion channel targets at concentrations up to 10 micromolar [1].

The pharmacological profile of RO5256390 in preclinical models encompasses suppression of psychostimulant-induced hyperlocomotion, reduction of cocaine self-administration and context-induced relapse to cocaine seeking, blockade of compulsive binge-like eating, suppression of rapid eye movement (REM) sleep through TAAR1-dependent mechanisms, pro-cognitive activity in amyloid-beta-challenged mice and in primate executive function paradigms, reduction of motor hyperactivity in spontaneously hypertensive rat models of attention-deficit/hyperactivity disorder, and acute inhibition of ventral tegmental area dopaminergic and dorsal raphe serotonergic neuron firing that reverses to enhanced excitability upon chronic administration [1, 3, 4, 5, 6, 7, 8]. Recent structural biology has resolved the cryo-electron microscopy structure of the RO5256390-bound human TAAR1-Gs heterotrimer signaling complex at 2.80 angstrom resolution (PDB 8W8A), revealing the molecular determinants of agonist recognition within the orthosteric binding pocket [9].

RO5256390 has not entered human clinical trials. It remains a preclinical tool compound positioned within a broader TAAR1 agonist program that produced the clinical candidates ulotaront (SEP-363856; TAAR1/5-HT1A dual agonist, Phase 3 completed with negative primary endpoint results in 2023) and ralmitaront (RO6889450; TAAR1 partial agonist, Phase 2). The compound is commercially available from multiple research chemical suppliers (Sigma-Aldrich, MedChemExpress, MedKoo, Cayman Chemical) at greater than 98 percent purity and is the reference full agonist for in vitro and in vivo TAAR1 pharmacology. This monograph documents the chemistry, receptor pharmacology, preclinical evidence base across psychiatric, cognitive, addictive, metabolic, and sleep-wake indications, the structural biology of the TAAR1 binding interaction, sourcing and handling, stack considerations, safety signal, and a structured comparative assessment against five TAAR1-targeting agents on five competency standards.